Diaxonhit: CITHY clinical study starts for Dx15 molecular

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Diaxonhit: CITHY clinical study starts for Dx15 molecular test validation

DIAXONHIT - Thyroid cancer test

CITHY clinical study starts

for Dx15 molecular test validation

  • Diagnostic prospective multicenter study with approximately 1,000 patients
  • European positioning of the test with about 20 clinical centers
  • First patients already included
  • At stake: a reduction in the number of unnecessary thyroid surgeries

PARIS, Nov. 18, 2014 (GLOBE NEWSWIRE) -- DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, announces that the clinical study for the validation of Dx15, a molecular test for thyroid cancer, recently started. The goal of Dx15 is to enable surgeons to assess the benign or malignant status of a thyroid nodule when cytological analysis remains indeterminate. DIAXONHIT is the sponsor of this study entitled CITHY (Cytologie Indéterminée de la THYroïde - Indeterminate Thyroid Cytology), which received a favorable opinion from regulatory authorities. As of October 31, 2014, the first patients were already included in France.

In 2012, the Caisse Nationale d'Assurance Maladie (French CMS) found that 7,270 thyroid ablations were performed in France, while identified nodules that were analyzed post-surgery were benign. To avoid such unnecessary, costly and invasive surgeries, a sample from the suspicious nodule is collected by fine needle aspiration and analyzed by a cytopathologist. However, approximately 20% of such analyses remain inconclusive since the benign or malignant status cannot be determined. The objective of DX15 is to perform a more detailed molecular analysis of indeterminate samples in order to minimize unnecessary surgeries. In this context, such a test would bring considerable benefit to both patients and payers.

DIAXONHIT successfully completed the first two phases of development of DX15. During an initial feasibility study, more than 200 biomarkers that showed a statistically significant difference between benign and malignant nodules, were first identified. It was followed by an identification phase in which several very promising transcriptomic signatures were selected, with different molecular profiles than those of US competitors. With the CITHY clinical study, the final stage of development aims at determining DX15 clinical performance on a statistically significant basis.

In this context, the CITHY study will recruit approximately 1,000 patients in twenty European clinical centers, all experts in the diagnosis and monitoring of thyroid cancer. This positioning, deliberately expanded at the beginning of the validation study, allows DIAXONHIT to collaborate at onset with a panel of leading experts in Europe. It should also enable a greater number of patients to rapidly benefit from DX15 as soon as validated.

" I want to congratulate our teams who completed on schedule the steps required to initiate the CITHY study. The enthusiasm of clinicians for DX15 is an encouragement to focus our efforts so that this test be made quickly available to thyroid cancer specialists. DX15 will strengthen our portfolio of diagnostic tests in the growing specialty field of oncology. " said Dr. Loïc Maurel, President of the Management Board of Diaxonhit.

Professor Jean-Louis Wémeau of the University Hospital in Lille, CITHY study coordinator for France, added: " The cytology of thyroid nodules, now codified according to the Bethesda classification, has become a key examination in order to define subsequent patient care. However, in a significant number of cases, this analysis ends up being indeterminate, and the benign or malignant nature of the thyroid sample cannot be identified. In this context, the contribution of a new molecular test such as DX15 could be very valuable, and the CITHY study will allow us to evaluate its clinical utility . "

About the CITHY study

The CITHY clinical study (Cytologie Indéterminée de la THYroïde - indeterminate thyroid cytology) is a multicenter prospective diagnostic study. The main objective of this blind study is to validate the diagnostic performance of DIAXONHIT's DX15 molecular test on transcriptomic signatures, previously identified on separate cohorts of samples, for the determination of the malignant or benign status of thyroid nodules which cytology proved indeterminate. The target population includes categories III (atypia of indeterminate significance or follicular lesion of indeterminate significance (AUS / FLUS)) and IV (follicular neoplasm or suspicion of follicular neoplasm (FN / SFN)) of the Bethesda classification. This study received a favorable opinion from the Ethics Committee on July 1, 2014 and authorization from ANSM (French health authority) on August 6, 2014.

The study plans to include about 1000 patients in twenty European investigation centers, all experts in the diagnosis and monitoring of thyroid cancer. All patients will be followed until obtaining the malignancy or benignity status of nodules, that will be subject to cytology following a fine needle aspiration, by histological analysis of the surgical specimen or, in its absence, of clinical monitoring. The duration of the inclusion period is estimated at about 14 months.

Monitoring of patients who underwent surgery will be performed until histological results are provided. For no-surgery patients, monitoring will last for a minimum of one year from inclusion. The clinical assessment of patients without surgery will continue for up to 12 months after the last patient enters the study in order to benefit from extended follow-up for patients entering early into the study. Given the length of monitoring, the total duration of the study should be approximately 26 months from the first recruitment.

About DIAXONHIT

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in in vitro diagnostics, involved from research to commercialization of specialty diagnostic products in the fields of transplantation, infectious diseases and cancer. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment, quality control products and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest commercial partner worldwide. The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering its three main specialty areas: transplantation, immuno-infection and cancer. Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of both the NYSE Alternext OSEO Innovation and the Next Biotech indices.

For more information, please visit: http://www.diaxonhit.com

Symbol : ALEHT - ISIN Code: FR0004054427  -  Reuters : ALEHT.PA  - Bloomberg : ALEHT:FP

Contacts

DIAXONHIT
Hervé Duchesne de Lamotte, CFO, +33 (0)1 53 94 52 49, herve.delamotte@diaxonhit.com

NewCap
Julien Perez, Investors Relations & Financial Communication, +33 (0)1 44 71 98 52, jperez@newcap.fr
Annie-Florence Loyer, Media Relations, +33 (0)1 44 71 98 50, afloyer@newcap.fr

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Press release http://hugin.info/159969/R/1871482/658455.pdf

HUG#1871482

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 66

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 174

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 33

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Harbour BioMed's LET003 Gets China's IND Green Light

Updated Category News Views 64

Muscle loss has become the awkward fact sitting beside every blockbuster obesity headline. Harbour BioMed's Nov. 18 announcement that China's National Medical Products Administration accepted its IND application for LET003 matters because the company is aiming directly at that problem: losing fat without giving away too much lean mass along the way. Acceptance Opens a...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 25

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 56

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

KLA Corporation Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 118

KLA Corporation Declares Cash Dividend for Investors The KLA Corporation (NASDAQ: KLAC), renowned for its innovation within the electronics industry, has taken a significant step to reward its shareholders. The Board of Directors recently announced a quarterly cash dividend of $1.90 per share. This decision reflects KLA's commitment to delivering value to its investors...

Continue Reading
Peptone Market Growth Projected to Reach $240.5 Million

Updated Category News Views 170

Overview of the Peptone Market The peptone market is on an impressive growth trajectory, expected to reach an estimated value of $240.5 million by 2035. This significant growth is attributed to a compound annual growth rate (CAGR) of 4.2% from 2024 to 2035. The driving forces behind this trend include rising demand in biopharmaceutical production, the application of...

Continue Reading
Roch Dog Introduces Innovative AI Certification for Hotels

Updated Category News Views 310

Revolutionizing Pet-Friendly Travel with AI Roch Dog, an NVIDIA Inception startup, has disrupted the hotel industry by launching the first AI certification engine focused on pet-friendly hotels. This innovative platform streamlines the processes of assessment, certification, ranking, and review of hotels based on their pet-friendly offerings. With a commitment to...

Continue Reading
Major Holdings Update from Wellington Management Group LLP

Updated Category News Views 198

Understanding Major Holdings Notifications In the world of finance and investments, major holdings notifications play a vital role in maintaining transparency and trust among investors and stakeholders. This process helps companies keep everyone informed about significant changes in ownership, which can impact decision-making and share prices. Today, we will delve into...

Continue Reading
German Housing Market Shows Signs of Recovery Amid Declines

Updated Category News Views 148

Recent Trends in the German Housing Market In the second quarter, Germany saw a significant drop in residential property prices, averaging a decrease of 2.6% compared to last year. However, a new report from the federal statistics office reveals some encouraging signs that suggest the market may be stabilizing. Quarterly Growth Despite Yearly Declines While the annual...

Continue Reading